Table 2.
First-line eradication rates of Helicobacter pylori
| Achieved/analyzed patients (n) | Eradication rate, (95%CI) | P value1 | P value2 | |
| Per protocol | 0.001 | |||
| PAC (n = 143) | 109/143 | 76.2% (69.3-83.2) | < 0.001 | |
| PAM (n = 139) | 117/139 | 84.2% (78.1-90.2) | 0.016 | |
| Sequential (n = 141) | 119/141 | 84.4% (78.4-90.4) | 0.018 | |
| Concomitant (n = 143) | 135/143 | 94.4% (90.6-98.2) | - | |
| Intent-to-treat | 0.001 | |||
| PAC (n = 170) | 109/170 | 64.1% (58.8-73.0) | 0.007 | |
| PAM (n = 170) | 117/170 | 68.8% (66.3-79.2) | 0.285 | |
| Sequential (n = 170) | 119/170 | 70.7% (65.0-78.5) | 0.169 | |
| Concomitant (n = 170) | 135/170 | 79.4% (74.6-86.5) | - |
1
P-value of χ2 test;
2
Bonferroni adjusted P-value of χ2 test on 2 × 2 subtables. PAC: Rabeprazole, amoxicillin and clarithromycin; PAM: Rabeprazole, amoxicillin and metronidazole.